381 studies found for:    Open Studies | Exclude Unknown | "heart disease"OR"stroke"OR"cardiovascular disease" | United States | Phase 1, 2, 3, 0 | Industry
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | Exclude Unknown | "heart disease"OR"stroke"OR"cardiovascular disease" | United States | Phase 1, 2, 3, 0 | Industry
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
Condition: Stroke
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
2 Recruiting Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Condition: Chronic Ischemic Stroke
Interventions: Biological: SB623 Implant (2.5M);   Biological: SB623 Implant (5.0M);   Procedure: Sham surgery
3 Recruiting Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
Conditions: Acute Ischemic Stroke;   Thrombotic Disease
Interventions: Drug: DS-1040b;   Drug: placebo
4 Recruiting Safety Evaluation of 3K3A-APC in Ischemic Stroke
Condition: Ischemic Stroke
Interventions: Biological: 3K3A-APC;   Drug: Placebo
5 Recruiting HT-3951 vs. Placebo in Stroke Rehabilitation
Condition: Ischemic Stroke
Interventions: Drug: HT-3951;   Drug: Placebo
6 Not yet recruiting A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes
Condition: Ischemic Stroke
Intervention: Drug: TF0023
7 Recruiting Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Condition: Stroke
Interventions: Drug: GM602;   Drug: Matching Placebo (Bacteriostatic Saline) for GM602
8 Recruiting Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Drug: natalizumab;   Drug: Placebo
9 Recruiting Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
Conditions: Stroke;   Secondary Prevention
Interventions: Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
10 Recruiting A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Conditions: Heart Failure;   Coronary Artery Disease
Interventions: Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
11 Recruiting Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities
Condition: Cardiovascular Disease
Interventions: Drug: Febuxostat;   Drug: Allopurinol
12 Recruiting Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
Condition: Ischemic Stroke
Interventions: Device: The Ischemic Stroke System;   Device: Sham control
13 Recruiting Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Conditions: Aortic Valve Stenosis;   Cardiovascular Diseases;   Heart Valve Diseases;   Ventricular Outflow Obstruction;   Thrombosis
Interventions: Drug: Acetylicsalicylic acid;   Drug: Clopidogrel;   Drug: Rivaroxaban
14 Recruiting An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study
Condition: Post-ischemic Stroke
Interventions: Drug: dalfampridine-ER 7.5 mg;   Drug: dalfampridine-ER 10 mg
15 Recruiting A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Conditions: Heart Failure;   Respiratory Insufficiency;   Stroke Acute;   Infectious Diseases;   Rheumatic Diseases
Interventions: Drug: Rivaroxaban, 10 mg;   Drug: Rivaroxaban, 7.5 mg;   Drug: Placebo
16 Recruiting Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Condition: Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions: Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
17 Recruiting The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Condition: Cardiovascular Disease
Interventions: Drug: bococizumab (PF-04950615);   Drug: Placebo
18 Recruiting Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk
Conditions: Hypercholesterolemia;   Atherosclerotic Cardiovascular Diseases
Interventions: Drug: ETC-1002;   Drug: Placebo
19 Recruiting A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
Condition: Prostate Cancer
Interventions: Drug: Degarelix;   Drug: Leuprolide
20 Recruiting Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Conditions: Transient Ischemic Attack;   Stroke;   Atrial Fibrillation
Interventions: Drug: Apixaban;   Drug: Warfarin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years